The stock options have a ten-year term, and the exercise price is $30.40 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options and RSUs. The ...

According to the prospectus, Vor Biopharma will not receive any proceeds from the sale of shares by the selling stockholders, though the company would receive proceeds from any warrants exercised for ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...

Vor Biopharma Inc (NASDAQ:VOR) saw its stock decline 3.4% in premarket trading Thursday after the company filed a preliminary prospectus for the potential resale of up to 50,999,999 shares of its ...